Both AHR inhibitor and STUB-1 activator significantly mitigated IS and uremic serum-mediated thrombosis in flow loops coated with vSMCs, in a FeCl3-induced carotid artery injury model in the setting of CKD, and in an IS-specific solute model [88]. Here, AHR is linked to chronic kidney disease.